Mass General Brigham Launches Genetic Test Developed in Collaboration with Broad Clinical Labs to Predict Risk Across Eight Cardiovascular Conditions

BOSTON, Sept. 3, 2025 /PRNewswire/ — In a step forward for genomic-driven preventive medicine, Mass General Brigham Personalized Medicine and the Massachusetts General Hospital’s Cardiovascular Disease Prevention Center and Center for Genomic Medicine today announced the launch of an innovative genetic test designed to estimate an individual’s inherited risk for eight chronic cardiovascular conditions. The clinician-ordered test is now available to patients on a self-pay basis.

Developed in collaboration with the Broad Clinical Labs and the Mass General Brigham Laboratory for Molecular Medicine (LMM), the test integrates advanced genomic insights with clinical-grade reporting to provide a comprehensive view of a patient’s inherited cardiovascular disease risk.

This tool assesses an individual’s genetic predisposition to a range of common and serious health conditions, including atrial fibrillation, coronary artery disease, type 2 diabetes mellitus, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. By identifying inherited risk factors, the tool supports earlier intervention and more personalized approaches to disease prevention and management.